The board / Semaglutide 2.4 mg vs Survodutide
Injectable division

Semaglutide 2.4 mg (Wegovy)

BCompetitive
Novo Nordisk · approved
vs
Injectable division

Survodutide

LaggingC
Boehringer Ingelheim · certified
12% · leads
Efficacy
8%
Mild (+3.9) · gentler
Tolerability
Heavy (+17.3)
Subcutaneous injection
Route
Subcutaneous injection
None
Food / water rule
None
Refrigerated (room temperature up to 28 days)
Storage
Refrigerated
The call: Semaglutide 2.4 mg leads on efficacy: competitive to Survodutide's lagging (12% vs 8%). Semaglutide 2.4 mg is the easier of the two to stay on (Mild vs Heavy).
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Winners are called only across a tier or band boundary; within one, the drugs are effectively tied. The side marked leads or gentler wins that axis.

Semaglutide 2.4 mg verdict · Survodutide verdict · How this is scored